About Alpha-amylase 1A
Alpha-amylase 1A (AMY1A) is a protein
from Homo sapiens identified by UniProt accession
P0DUB6, 511 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Alpha-amylase 1A |
| UniProt accession | P0DUB6 |
| Gene | AMY1A |
| Organism | Homo sapiens |
| Length | 511 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (14)
Diseases linked to this target (Open Targets).
- lung adenocarcinoma · score 0.18
- leukocyte count · score 0.08
- blood protein measurement · score 0.05
- dentures · score 0.04
- dental caries · score 0.02
- Obesity · score 0.02
- Alzheimer disease · score 0.01
- esophageal squamous cell carcinoma · score 0.00
- cancer · score 0.00
- chronic fatigue syndrome · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0DUB6-F1 | alphafold | PREDICTED | 96.70 | — |
Amino-acid sequence (511 residues)
MKLFWLLFTI GFCWAQYSSN TQQGRTSIVH LFEWRWVDIA LECERYLAPK GFGGVQVSPP NENVAIHNPF RPWWERYQPV SYKLCTRSGN EDEFRNMVTR CNNVGVRIYV DAVINHMCGN AVSAGTSSTC GSYFNPGSRD FPAVPYSGWD FNDGKCKTGS GDIENYNDAT QVRDCRLSGL LDLALGKDYV RSKIAEYMNH LIDIGVAGFR IDASKHMWPG DIKAILDKLH NLNSNWFPEG SKPFIYQEVI DLGGEPIKSS DYFGNGRVTE FKYGAKLGTV IRKWNGEKMS YLKNWGEGWG FMPSDRALVF VDNHDNQRGH GAGGASILTF WDARLYKMAV GFMLAHPYGF TRVMSSYRWP RYFENGKDVN DWVGPPNDNG VTKEVTINPD TTCGNDWVCE HRWRQIRNMV NFRNVVDGQP FTNWYDNGSN QVAFGRGNRG FIVFNNDDWT FSLTLQTGLP AGTYCDVISG DKINGNCTGI KIYVSDDGKA HFSISNSAED PFIAIHAESK L
Explore Alpha-amylase 1A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets